Swedish pharmaceutical company Newbury Pharmaceuticals AB (STO:NEWBRY) announced on Friday that it has obtained Marketing Authorization in Denmark for Palbociclib Newbury tablets, marking the first approval within a Scandinavian registration procedure.
Approvals in Sweden and Norway are expected following completion of national regulatory reviews.
A generic version of Ibrance, Palbociclib Newbury is a selective CDK4 and CDK6 inhibitor indicated for the treatment of HR-positive and HER2-negative breast cancer. The Scandinavian market for the product is estimated at EUR21m annually, according to DLMI Nordic Pharma Insights.
Newbury plans to launch the product in relevant markets once regulatory exclusivities and patent constraints allow.
Lupin announces US launch of Azilsartan Medoxomil Tablets
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval